Shridar Ganesan, MD, PhD

I came to The Cancer Institute of New Jersey in 2005 from the Dana-Farber Cancer Institute/Harvard Medical School where I was an instructor in medicine and staff physician. I started my medical training at Yale University, where I graduated from with both an MD and a PhD in cell biology. I then completed a medical residency at the Brigham and Women’s Hospital in Boston and served as a Chief Medical Resident. This was followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.

With a research interest in breast cancer biology and DNA repair, I am currently exploring how DNA repair defects in cancers can be exploited to develop novel effective treatments. I am also active in applying next-generation sequencing technology to identify specific genomic changes in cancers that can be therapeutically targeted. As a physician/scientist I both run a basic research laboratory focused on breast cancer biology and see patients in the Stacy Goldstein Breast Cancer Center. In the clinic, I work collaboratively with experts across multi-disciplines and have the opportunity to put theory into practice as we aim to develop the next generation of targeted treatments for breast cancer. Working with a team of radiation oncologists, surgical oncologists, nurses, social workers, genetic specialists and others, I help patients understand their specific disease and their treatment options so that they can make informed decisions. I am also an associate professor of medicine and pharmacology at Robert Wood Johnson Medical School.

I am the author or co-author of more than 40 publications and serve on the editorial board of the journal Frontiers in Molecular and Cellular Oncology.